• Explore /
  • Poster
  • / A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale.

A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale.

Abstract Poster

Authors

null

Omar Saavedra Santa Gadea

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain

Omar Saavedra Santa Gadea , Elena Garralda , Juanita Suzanne Lopez , Mark M. Awad , Jacob Stephen Thomas , Crescens Diane Tiu , Daniela Morales-Espinosa , Christa Raab , Bettina Rehbein , Gabriele Hintzen , Kerstin Pietzko , Paulien Ravenstijn , Michael Emig , Anthony B. El-Khoueiry

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Clinical Trial Registration Number

NCT04259450

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2672)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2672

Abstract #

TPS2672

Poster Bd #

325a

Abstract Disclosures

Similar Posters

First Author: Yan Zhang

First Author: Kyriakos P. Papadopoulos

First Author: Kaiwen Li

First Author: Anthony B. El-Khoueiry